| Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trial GG Schwartz, AG Olsson, MD Ezekowitz, P Ganz, MF Oliver, D Waters, ... Jama 285 (13), 1711-1718, 2001 | 3745 | 2001 |
| Alirocumab and cardiovascular outcomes after acute coronary syndrome GG Schwartz, PG Steg, M Szarek, DL Bhatt, VA Bittner, R Diaz, ... New England Journal of Medicine 379 (22), 2097-2107, 2018 | 2654 | 2018 |
| Effects of dalcetrapib in patients with a recent acute coronary syndrome GG Schwartz, AG Olsson, M Abt, CM Ballantyne, PJ Barter, J Brumm, ... New England Journal of Medicine 367 (22), 2089-2099, 2012 | 2265 | 2012 |
| Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR Trial) PH Jones, MH Davidson, EA Stein, HE Bays, JM McKenney, E Miller, ... The American journal of cardiology 92 (2), 152-160, 2003 | 2192 | 2003 |
| Pioglitazone after ischemic stroke or transient ischemic attack WN Kernan, CM Viscoli, KL Furie, LH Young, SE Inzucchi, M Gorman, ... New England Journal of Medicine 374 (14), 1321-1331, 2016 | 1155 | 2016 |
| ODYSSEY OUTCOMES Committees and Investigators. Alirocumab and cardiovascular outcomes after acute coronary syndrome GG Schwartz, PG Steg, M Szarek, DL Bhatt, VA Bittner, R Diaz, ... N Engl J Med 379 (22), 2097-2107, 2018 | 651 | 2018 |
| High-dose atorvastatin enhances the decline in inflammatory markers in patients with acute coronary syndromes in the MIRACL study S Kinlay, GG Schwartz, AG Olsson, N Rifai, SJ Leslie, WJ Sasiela, ... Circulation 108 (13), 1560-1566, 2003 | 585 | 2003 |
| Effect of alirocumab, a monoclonal antibody to PCSK9, on long-term cardiovascular outcomes following acute coronary syndromes: rationale and design of the ODYSSEY outcomes trial GG Schwartz, L Bessac, LG Berdan, DL Bhatt, V Bittner, R Diaz, ... American heart journal 168 (5), 682-689. e1, 2014 | 566 | 2014 |
| Baseline and on-statin treatment lipoprotein (a) levels for prediction of cardiovascular events: individual patient-data meta-analysis of statin outcome trials P Willeit, PM Ridker, PJ Nestel, J Simes, AM Tonkin, TR Pedersen, ... The Lancet 392 (10155), 1311-1320, 2018 | 463 | 2018 |
| Effect of alirocumab on lipoprotein (a) and cardiovascular risk after acute coronary syndrome VA Bittner, M Szarek, PE Aylward, DL Bhatt, R Diaz, JM Edelberg, Z Fras, ... Journal of the American College of Cardiology 75 (2), 133-144, 2020 | 350 | 2020 |
| High-dose atorvastatin reduces total plasma levels of oxidized phospholipids and immune complexes present on apolipoprotein B-100 in patients with acute coronary syndromes in … S Tsimikas, JL Witztum, ER Miller, WJ Sasiela, M Szarek, AG Olsson, ... Circulation 110 (11), 1406-1412, 2004 | 347 | 2004 |
| Varespladib and cardiovascular events in patients with an acute coronary syndrome: the VISTA-16 randomized clinical trial SJ Nicholls, JJP Kastelein, GG Schwartz, D Bash, RS Rosenson, ... Jama 311 (3), 252-262, 2014 | 331 | 2014 |
| Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACL) Study Investigators. Effects of atorvastatin on early recurrent ischemic events in acute coronary … S GG Jama 285, 1711-1718, 2001 | 277 | 2001 |
| High-density lipoprotein, but not low-density lipoprotein cholesterol levels influence short-term prognosis after acute coronary syndrome: results from the MIRACL trial AG Olsson, GG Schwartz, M Szarek, WJ Sasiela, MD Ezekowitz, P Ganz, ... European heart journal 26 (9), 890-896, 2005 | 276 | 2005 |
| Fasting triglycerides predict recurrent ischemic events in patients with acute coronary syndrome treated with statins GG Schwartz, M Abt, W Bao, D DeMicco, D Kallend, M Miller, H Mundl, ... Journal of the American College of Cardiology 65 (21), 2267-2275, 2015 | 265 | 2015 |
| Effects of early treatment with statins on short-term clinical outcomes in acute coronary syndromes: a meta-analysis of randomized controlled trials M Briel, GG Schwartz, PL Thompson, JA De Lemos, MA Blazing, ... Jama 295 (17), 2046-2056, 2006 | 255 | 2006 |
| Effects of alirocumab on cardiovascular and metabolic outcomes after acute coronary syndrome in patients with or without diabetes: a prespecified analysis of the ODYSSEY … KK Ray, HM Colhoun, M Szarek, M Baccara-Dinet, DL Bhatt, VA Bittner, ... The lancet Diabetes & endocrinology 7 (8), 618-628, 2019 | 251 | 2019 |
| Association of perioperative β-blockade with mortality and cardiovascular morbidity following major noncardiac surgery MJ London, K Hur, GG Schwartz, WG Henderson Jama 309 (16), 1704-1713, 2013 | 251 | 2013 |
| Effects of atorvastatin on stroke in patients with unstable angina or non-Q-wave myocardial infarction: a Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering … DD Waters, GG Schwartz, AG Olsson, A Zeiher, MF Oliver, P Ganz, ... Circulation 106 (13), 1690-1695, 2002 | 247 | 2002 |
| Effect of aleglitazar on cardiovascular outcomes after acute coronary syndrome in patients with type 2 diabetes mellitus: the AleCardio randomized clinical trial AM Lincoff, JC Tardif, GG Schwartz, SJ Nicholls, L Rydén, B Neal, ... Jama 311 (15), 1515-1525, 2014 | 239 | 2014 |
